Short Interest in Agenus Inc. (NASDAQ:AGEN) Expands By 6.5%

Agenus Inc. (NASDAQ:AGEN) saw a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 2,930,000 shares, an increase of 6.5% from the November 30th total of 2,750,000 shares. Based on an average daily trading volume, of 494,100 shares, the days-to-cover ratio is currently 5.9 days. Approximately 13.1% of the company’s shares are sold short.

Agenus Stock Performance

Shares of NASDAQ AGEN opened at $2.74 on Thursday. Agenus has a fifty-two week low of $2.50 and a fifty-two week high of $19.69. The company has a market cap of $64.28 million, a price-to-earnings ratio of -0.24 and a beta of 1.24. The business’s 50 day moving average price is $3.34 and its 200-day moving average price is $6.21.

Institutional Trading of Agenus

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC grew its holdings in shares of Agenus by 7.1% in the third quarter. Geode Capital Management LLC now owns 483,059 shares of the biotechnology company’s stock worth $2,648,000 after purchasing an additional 32,016 shares during the last quarter. State Street Corp grew its stake in Agenus by 2.1% in the 3rd quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock worth $2,563,000 after acquiring an additional 9,731 shares in the last quarter. Walleye Capital LLC purchased a new position in shares of Agenus during the third quarter worth approximately $1,003,000. Federated Hermes Inc. bought a new stake in shares of Agenus during the second quarter valued at approximately $1,921,000. Finally, FMR LLC boosted its holdings in shares of Agenus by 47.1% in the third quarter. FMR LLC now owns 85,301 shares of the biotechnology company’s stock valued at $467,000 after purchasing an additional 27,309 shares during the period. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Agenus in a research note on Thursday, December 5th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, Agenus has a consensus rating of “Hold” and a consensus price target of $10.00.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.